ANI Pharmaceuticals (ANIP)

[Just the facts maam]

I was reading through some of the SEC filings related to the Spin off of AbbVie from Abbott. January 1st marks the 5th anniversary of the divorce. In the agreement Abbott would continued manufacturing products for up to 5 years. One of the products Abbott manufactured for AbbVie included Creon which brought in $215 million in revenue last quarter.

Seeing that Dr. Karen Quinn was instrumental in getting Creon approved under the new guidelines. Don't be surprised if in addition to advancing the Corti drugs, she is working on the transfer of manufacturing of Creon Abbott facilities to Anip's facility in BAudette.

Manufacturing and Supply Agreements

AbbVie will enter into finished good supply agreements and contract manufacturing agreements with Abbott prior to the distribution pursuant to which AbbVie or Abbott, as the case may be, will manufacture, label, and package products for the other party. Under the finished goods supply agreements, Abbott will manufacture for AbbVie the active pharmaceutical ingredients for Trilipix, Depakote, and Biaxin, in each case to be sold in the United States. Abbott will also supply to AbbVie the active pharmaceutical ingredient for Tarka to be sold in the United States and Luvox to be sold in Japan. In addition, Abbott will manufacture for AbbVie Creon to be sold in the United States, and tubing for Duodopa. Under the contract manufacturing agreements, Abbott will provide AbbVie with local packaging services for HUMIRA, Kaletra, Norvir, and Synagis for Japan, local packaging services for HUMIRA, Kaletra, Lupron, Norvir, Simdax, Survanta, Synagis, and Zemplar for Mexico, local packaging services for HUMIRA, Kaletra, Norvir, and Survanta for Argentina, and local filling and packaging services for Sevoflurane (for human use) and Forane for Latin America. In addition, AbbVie will enter into finished goods supply agreements and contract manufacturing agreements with Abbott to manufacture for Abbott Special Products and certain other pharmaceutical products.

These manufacturing and supply agreements will have a term of up to five years